Nanoparticle (NP)-based therapeutics have ushered in a new era in translational medicine.
However, despite the clinical success of NP technology, it is not well-understood how NPs …

Upon contact with a biological milieu, nanomaterials tend to interact with biomolecules
present in the media, especially proteins, leading to the formation of the so-called “protein …

How soft corona, the protein corona's outer layer, contributes to biological identity of
nanomaterials is largely because capturing protein composition of the soft corona in situ …

Extracellular vesicles (EVs) in human blood are a potential source of biomarkers. To which
extent anticoagulation affects their concentration, cellular origin and protein composition is …

The current understanding of the biological identity that nanoparticles may acquire in a
given biological milieu is mostly inferred from the hard component of the protein corona …

Recent advances in extracellular vesicle (EVs) detection and isolation methods have led to
the development of novel therapeutic modalities. Among different types of EVs, exosomes …

Although a wide variety of nanoparticles (NPs) have been engineered for use as disease
markers or drug delivery agents, the number of nanomedicines in clinical use has hitherto …

Nanomaterials have a huge potential in research fields from nanomedicine to medical
devices. However, surface modifications of nanoparticles (NPs) and thus of their …

Unpredictable and uncontrollable protein adsorption on nanoparticles remains a
considerable challenge to achieving effective application of nanotechnologies within …

Although an established drug delivery platform, liposomes have not fulfilled their true
potential. In the body, interactions of liposomes are mediated by the layer of plasma proteins …